

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation							
1. Given Name (First Name) Vance	2. Surname (Last Name) Fowler	3. Date 15-November-2019						
4. Are you the corresponding author?	✓ Yes No							
5. Manuscript Title Efficacy and Safety of Exebacase Addeo Bloodstream Infections Including Endo	Efficacy and Safety of Exebacase Added to Antibiotic Therapy versus Antibiotic Therapy Alone for Staphylococcus aureus							
6. Manuscript Identifying Number (if you k	now it)							
Section 2. The Work Under C	onsideration for Publication							
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?								
Are there any relevant conflicts of inter	est? 🖌 Yes 🗌 No							
If yes, please fill out the appropriate inf Excess rows can be removed by pressin	•	than one entity press the "ADD" button to add a row.						
Name of Institution/Company	Grant? Personal Non-Finan Fees? Support	Other Comments						
ontraFect Corporation		Consulting fees						

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

No

Are there any relevant conflicts of interest?  $\checkmark$  Yes

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
MedImmune	$\checkmark$	$\checkmark$			Grant/research support; consulting fees
Cerexa/Forest/Actavis/Allergan	$\checkmark$	$\checkmark$			Grant/research support; consulting fees (Cerexa); educational fees (Cerexa)



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Pfizer	$\checkmark$	$\checkmark$			Grant/research support; consulting fees
Advanced Liquid Logics	$\checkmark$				Grant/research support
Theravance	$\checkmark$	$\checkmark$		$\checkmark$	Grant/research support; consulting fees; educational fees
Novartis	$\checkmark$	$\checkmark$			Grant/research support; consulting fees
Cubist/Merck	$\checkmark$	$\checkmark$		$\checkmark$	Grant/research support; consulting fees (Cubist); educational fees (Cubist); Co-Chair V710 Vaccine (Merck)
Medical Biosurfaces	$\checkmark$				Grant/research support
Locus	$\checkmark$				Grant/research support
Affinergy	$\checkmark$				Grant/research support
Karius	$\checkmark$				Grant/research support
Genentec	$\checkmark$	$\checkmark$			Grant/research support; consulting fees
Regeneron	$\checkmark$	$\checkmark$			Grant/research support; consulting fees
Basilea	$\checkmark$	$\checkmark$			Grant/research support; consulting fees
Galderma		$\checkmark$			Consulting fees
Novadigm		$\checkmark$			Consulting fees
Durata		$\checkmark$		$\checkmark$	Consulting fees; educational fees
Debiopharm		$\checkmark$		$\checkmark$	Consulting fees; educational fees
Achaogen		$\checkmark$			Consulting fees
Affinium		$\checkmark$			Consulting fees
Medicines Co.		$\checkmark$			Consulting fees
Tetraphase		$\checkmark$			Consulting fees
Trius		$\checkmark$			Consulting fees
Bayer		$\checkmark$			Consulting fees
Affinergy		$\checkmark$			Consulting fees
Janssen		$\checkmark$			Consulting fees
xBiotech		$\checkmark$			Consulting fees
Destiny		$\checkmark$			Consulting fees



Green Cross			Educational fees
Section 4. Intellectual Propert	y Patents & Copyr	ights	
Do you have any patents, whether plann	ed, pending or issued, l	broadly relevant to the	e work? Yes 🖌 No
Contract C			
Section 5. Relationships not c	overed above		
Are there other relationships or activities potentially influencing, what you wrote i	•	ceive to have influence	ed, or that give the appearance of
Yes, the following relationships/cond	itions/circumstances a	re present (explain bel	ow):
$\checkmark$ No other relationships/conditions/cir	cumstances that prese	nt a potential conflict o	of interest
At the time of manuscript acceptance, jo On occasion, journals may ask authors to			ssary, update their disclosure statements. relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Fowler reports grants and personal fees from ContraFect Corporation, during the conduct of the study; grants and personal fees from MedImmune, grants, personal fees and other from Cerexa/Forest/Actavis/Allergan, grants and personal fees from Pfizer, grants from Advanced Liquid Logics, grants, personal fees and other from Theravance, grants and personal fees from Novartis, grants, personal fees and other from Cubist/Merck, grants from Medical Biosurfaces, grants from Locus, grants from Affinergy, grants from Karius, grants and personal fees from Genentec, grants and personal fees from Regeneron, grants and personal fees from Basilea, personal fees from Galderma, personal fees from Novadigm, personal fees and other from Durata, personal fees and other from Debiopharm, personal fees from Achaogen, personal fees from Affinium, personal fees from Medicines Co., personal fees from Tetraphase, personal fees from Trius, personal fees from Bayer, personal fees from Affinergy, personal fees from Janssen, personal fees from xBiotech, personal fees from Destiny, other from Green Cross, outside the submitted work.



**Evaluation and Feedback** 



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	ation						
1. Given Name (First Name) Anita	2. Surname (Last Name) Das	3. Date 06-November-2019					
4. Are you the corresponding author?		esponding Author's Name re Fowler					
5. Manuscript Title Efficacy and Safety of Exebacase Added to Antibiotic Therapy versus Antibiotic Therapy Alone for Staphylococcus aureus Bloodstream Infections Including Endocarditis							
6. Manuscript Identifying Number (if you kn	ow it)						
Section 2. The Work Under Co	onsideration for Publication						
		party (government, commercial, private foundation, etc.) fo itoring board, study design, manuscript preparation,	or				
Are there any relevant conflicts of intere	st? 🖌 Yes 🗌 No						
If yes, please fill out the appropriate info Excess rows can be removed by pressing		e than one entity press the "ADD" button to add a row	v.				
Name of Institution/Company	Grant? Personal Non-Finan Fees? Suppor	S Other Comments					
ContraFect Corporation							

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  $\checkmark$  Yes  $\square$  No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Achaogen		$\checkmark$			Consulting Fees
lterumTx		$\checkmark$			Consulting Fees
Paratek		$\checkmark$			Consulting Fees



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Nabriva		$\checkmark$			Consulting Fees
Wockhardt		$\checkmark$			Consulting fees
UTILITY		$\checkmark$			Consulting fees
Zavante		$\checkmark$			Consulting fees
Tetraphase		$\checkmark$			Consulting fees
Theravance		$\checkmark$			Consulting fees
Cempra		$\checkmark$			Consulting fees

# Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? 🗌 Yes

# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Das reports personal fees from ContraFect Corporation, during the conduct of the study; personal fees from Achaogen, personal fees from IterumTx, personal fees from Paratek, personal fees from Nabriva, personal fees from Wockhardt, personal fees from UTILITY, personal fees from Zavante, personal fees from Tetraphase, personal fees from Theravance, personal fees from Cempra, outside the submitted work.

🖌 No



**Evaluation and Feedback** 



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Penalties: Funds are coming in to you eryour institution due to you



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Joy	2. Surname (Last Name) Lipka-Diamond		3. Date 06-November-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Na Vance Fowler	ime
5. Manuscript Title Efficacy and Safety of Exebacase Adde Bloodstream Infections Including Endo		rsus Antibiotic Therapy Aloi	ne for Staphylococcus aureus
6. Manuscript Identifying Number (if you k	now it)		
Section 2. The Work Under C	Consideration for Publi	ication	
Did you or your institution <b>at any time</b> reco any aspect of the submitted work (includin statistical analysis, etc.)?			
Are there any relevant conflicts of inter			
If yes, please fill out the appropriate inf Excess rows can be removed by pressir		ve more than one entity pre	ess the ADD button to add a row.
Name of Institution/Company	Grant	on-Financial Support? Other? Co	mments
ContraFect Corporation		Cons	ulting fees
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as desc clicking the "Add +" box. You should re	ribed in the instructions. L	Ise one line for each entity;	add as many lines as you need by
Are there any relevant conflicts of inter	rest? Yes 🖌 No		
Section 4. Intellectual Prope	rty Patents & Copyri	ights	
Do you have any patents, whether plar	nned, pending or issued, b	roadly relevant to the work	? 🗌 Yes 🖌 No



#### Section 5.

#### **Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Lipka-Diamond reports personal fees from ContraFect Corporation, during the conduct of the study.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation					
1. Given Name (First Name) Raymond	2. Surname (Last Name) Schuch		3. Date 07-November-2019			
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Na Vance Fowler	ame			
5. Manuscript Title Efficacy and Safety of Exebacase Added to Antibiotic Therapy versus Antibiotic Therapy Alone for Staphylococcus aureus Bloodstream Infections Including Endocarditis						
6. Manuscript Identifying Number (if you kr	now it)					
		-				
Section 2. The Work Under C	onsideration for Public	cation				
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?						
Are there any relevant conflicts of intere						
If yes, please fill out the appropriate info Excess rows can be removed by pressin		/e more than one entity pr	ress the "ADD" button to add a row.			
Name of Institution/Company	Grant	n-Financial Support? Other? Co	omments			
ContraFect		I am	an employee of ContraFect			
Section 3. Relevant financial	activition outside the	ubmitted work				

#### Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

No

Are there any relevant conflicts of interest? ✓ Yes

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
ContraFect Corporation				$\checkmark$	I am an employee of ContraFect	



# Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? 🗸 Yes 🗌 No

If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.

Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments	
US Patent No. 9.889,181		✓				Title: Bacteriophage Lysin and Antibiotic Combinations Against Gram Positive Bacteria	
US Patent No. 9,499,594		$\checkmark$				Title: Biofilm Prevention, Disruption & Treatment w/ Bacteriophage Lysin	

#### Section 5.

Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

#### Section 6.

**Disclosure Statement** 

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Schuch reports other from ContraFect, during the conduct of the study; other from ContraFect Corporation, outside the submitted work; In addition, Dr. Schuch has a patent US Patent No. 9.889,181 issued, and a patent US Patent No. 9,499,594 issued.



**Evaluation and Feedback** 



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Penalties: Funds are coming in to you eryour institution due to you



Section 1. Identifying Inform	ation							
1. Given Name (First Name) Roger	2. Surname (Last Name) Pomerantz		3. Date 14-November-2019					
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Autho Vance Fowler	or's Name					
5. Manuscript Title Efficacy and Safety of Exebacase Added to Antibiotic Therapy versus Antibiotic Therapy Alone for Staphylococcus aureus Bloodstream Infections Including Endocarditis								
6. Manuscript Identifying Number (if you kr	now it)	-						
Section 2. The Work Under Co	onsideration for Public	ation						
Did you or your institution <b>at any time</b> receiption and aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, dat							
Are there any relevant conflicts of intere If yes, please fill out the appropriate info		e more than one enti	ty press the "ADD" button to add a row					
Excess rows can be removed by pressing								
Name of Institution/Company	Grant? Personal Non Fees? Su	-Financial Other?	Comments					
ContraFect			I am CEO and Chairman of ContraFect, the company that is developing exebacase.					
Section 3. Relevant financial	activities outside the s	ubmitted work.						
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions. Us	e one line for each er	ntity; add as many lines as you need by					
Are there any relevant conflicts of intere	est? Yes 🖌 No							
Section 4. Intellectual Proper	rty Patents & Copyrig	ıhts						
Do you have any patents, whether plan	ned, pending or issued, bro	oadly relevant to the	work? Yes 🖌 No					



#### Section 5.

#### **Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Pomerantz reports other from ContraFect, during the conduct of the study; .

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Povalties: Funds are coming in to you or your institution due to you



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Luis	2. Surname (Last Name) Jauregui	3. Date 12-November-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Name Vance G Fowler, Jr. MD, MHS
5. Manuscript Title Efficacy and Safety of Exebacase Adde Bloodstream Infections Including Endo		sus Antibiotic Therapy Alone for Staphylococcus aureus
6. Manuscript Identifying Number (if you k	now it)	_
Section 2. The Work Under C		
The Work Under C	Consideration for Public	cation
		a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter	rest? 🖌 Yes 🗌 No	
		ve more than one entity press the "ADD" button to add a row.
Excess rows can be removed by pressir	ng the "X" button.	
Name of Institution/Company	Grant <sup>?</sup> Personal Nor Fees <sup>?</sup> S	n-Financial Other? Comments
ContraFect Corporation		
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as desc	ribed in the instructions. U	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re <b>present during the 36 months prior to publication</b> .
Are there any relevant conflicts of inter	rest? Yes 🖌 No	
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plar	nned, pending or issued, br	roadly relevant to the work? 🗌 Yes 🛛 🗸 No



#### Section 5.

#### **Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Jauregui reports grants from ContraFect Corporation, during the conduct of the study; .

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Povalties: Funds are coming in to you or your institution due to you



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Adam	2. Surname (Last Name) Bressler	3. Date 10-November-2019
4. Are you the corresponding author?		responding Author's Name nce Fowler
5. Manuscript Title Efficacy and Safety of Exebacase Added Bloodstream Infections Including Endoo	.,	ntibiotic Therapy Alone for Staphylococcus aureus
6. Manuscript Identifying Number (if you kn	now it)	
Section 2. The Work Under Co	onsideration for Publication	n
	but not limited to grants, data mor	d party (government, commercial, private foundation, etc.) for nitoring board, study design, manuscript preparation,
•	prmation below. If you have mo	re than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Non-Fina Fees? Suppo	Other Comments
ContraFect Corporation		

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  $\checkmark$  Yes  $\square$  No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Theravance Biopharma		$\checkmark$				
Allergan		$\checkmark$				



# Section 4. Intellectual Property -- Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Bressler reports grants from ContraFect Corporation, during the conduct of the study; personal fees from Theravance Biopharma, personal fees from Allergan, outside the submitted work.

#### **Evaluation and Feedback**

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.

✓ No



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation	
1. Given Name (First Name) David	2. Surname (Last Name) Evans	3. Date 10-November-2019
4. Are you the corresponding author?	Yes Vonce G. Fowler	thor's Name
5. Manuscript Title Efficacy and Safety of Exebacase Added Bloodstream Infections Including Endo	d to Antibiotic Therapy versus Antibiotic Thera ocarditis	apy Alone for Staphylococcus aureus
6. Manuscript Identifying Number (if you kr	now it)	
Section 2. The Work Under Co	onsideration for Publication	
	eive payment or services from a third party (govern g but not limited to grants, data monitoring board, rest?	
	ormation below. If you have more than one er	ntity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Non-Financial Fees? Support? Other	? Comments
ContraFect Corporation		

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  $\checkmark$  Yes  $\square$  No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Merck	$\checkmark$					
Tetraphase	$\checkmark$	$\checkmark$				
AtoxBio	$\checkmark$	$\checkmark$				



# Section 4. Intellectual Property -- Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes ✓ No Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Evans reports grants from ContraFect Corporation, during the conduct of the study; grants from Merck, grants and personal fees from AtoxBio, outside the submitted work.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	hation			
1. Given Name (First Name) Gregory	2. Surname (Last Name) Moran		3. Date 13-November-2019	
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's N Vance G. Fowler	lame	
5. Manuscript Title Efficacy and Safety of Exebacase Added Bloodstream Infections Including Endo		rsus Antibiotic Therapy Alo	one for Staphylococcus aureus	
6. Manuscript Identifying Number (if you kr	now it)			
Section 2. The Work Under Co	onsideration for Publ	ication		
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?			-	c.) for
Are there any relevant conflicts of intere				
If yes, please fill out the appropriate info Excess rows can be removed by pressin		ve more than one entity pr	ress the "ADD" button to add a	row.
Name of Institution/Company	Grant? Personal No Fees?	on-Financial Support?	omments	
Contrafect		Gran	nt support for this clinical trial.	

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

No

Are there any relevant conflicts of interest?  $\checkmark$  Yes

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Nabriva	$\checkmark$	$\checkmark$			Grant support for clinical trial, consulting fee, speaking fee	



# Section 4. Intellectual Property -- Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): Yes, the following relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

# Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Moran reports grants from Contrafect, during the conduct of the study; grants and personal fees from Nabriva, outside the submitted work.

# **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation			
1. Given Name (First Name) Mark	2. Surname (Last Name) Rupp		3. Date 12-November-2019	
4. Are you the corresponding author?		Corresponding Author's Na Cara Cassino	ame	
5. Manuscript Title Efficacy and Safety of Exebacase Added Bloodstream Infections Including Endo		s Antibiotic Therapy Alor	ne for Staphylococcus aureus	
6. Manuscript Identifying Number (if you kr	now it)			
Section 2. The Work Under Co	onsideration for Publica	tion	_	
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?				.) for
Are there any relevant conflicts of intere If yes, please fill out the appropriate info		mara than and antity pr	ass the "ADD" button to add a r	
Excess rows can be removed by pressin		more than one entity pre	ess the ADD button to add a h	0.00
Name of Institution/Company	Grant	Financial Other? Comport?	mments	
ContraFect			arch contract to UNMC to luct phase II trial	

Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? Yes No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Citius		$\checkmark$			Dr Rupp serves on advisory board for Citius. Citius is developing catheter lock solution that could be useful for treating catheter infections, including those caused by staphylococci



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
3М		$\checkmark$			Dr Rupp has served as a consultant for 3M on projects related to infection prevention. 3M manufactures wide variety of healthcare products - some of which are directed at preventing infections, including those caused by staphylococci	
Magnolia	<				Research contract to UNMC fro the study of blood culture diversion device to prevent blood culture contamination, including contamination caused by staphylococci	

#### Section 4.

**Intellectual Property -- Patents & Copyrights** 

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Ves

# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



Section 6.

**Disclosure Statement** 

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rupp reports grants from ContraFect, during the conduct of the study; personal fees from Citius, personal fees from 3M, grants from Magnolia, outside the submitted work.

**Evaluation and Feedback** 



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to you



Section 1. Identifying Inform	ation	_			
1. Given Name (First Name) Robert	2. Surname (Last Name Wise	)		3. Date 11-November-2019	
4. Are you the corresponding author?	Yes 🖌 No	Correspond Vance G. F	ling Author's owler	Name	
5. Manuscript Title Efficacy and Safety of Exebacase Added Bloodstream Infections Including Endoo 6. Manuscript Identifying Number (if you kn	carditis	versus Antibiotio	c Therapy A	None for Staphylococcus aureus	
Section 2. The Work Under Co	onsideration for Pub	olication			
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants,	, data monitoring			:.) for
If yes, please fill out the appropriate info Excess rows can be removed by pressing		nave more than	one entity	press the "ADD" button to add a	row.
Name of Institution/Company	Grant? Personal M Fees?	Non-Financial Support <b>?</b>	Other?	Comments	
Contrafect			RA ac stu th	ne study was funded by Contrafect. AW served on the clinical djudication committee for this udy. This activity is managed by ie Johns Hopkins Office of Policy pordination.	

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  $\checkmark$  Yes

No



Name of Entity	Grant?	Personal Fees?	Non-Financial Support <sup>?</sup>	Other?	Comments
AstraZeneca / Medimmune / Pearl	$\checkmark$	$\checkmark$			data monitoring committee, grants, consulting
Boehringer Ingelheim	$\checkmark$	$\checkmark$			steering committee, data monitoring committee, grants
Contrafect		$\checkmark$			clinical endpoint committee
Pulmonx		$\checkmark$			data safety monitoring committee
Roche		$\checkmark$			Data monitoring committee
Spiration		$\checkmark$			Steering committee
Sunovion		$\checkmark$			Workshop, consulting
Pearl Therapeutics	$\checkmark$				Research grant
Merck		$\checkmark$			Data monitoring committee
Circassia		$\checkmark$			Consultant
Pneuma		$\checkmark$			Consultant
Verona		$\checkmark$			Consultant
Mylan/Theravance		$\checkmark$			Consultant
Propeller Health		$\checkmark$			Consultant
Sanofi-Aventis	$\checkmark$				Research Grant
AbbVie		$\checkmark$			Data Monitoring Committee
GSK	$\checkmark$	$\checkmark$			Scientific advisory board, Clinical Endpoint committee, Data Monitoring Committee, research grant support.
Novartis		$\checkmark$			Consultant
Kiniksa		$\checkmark$			Pulmonary Safety Review Committee

Section 4.

## Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?

🖌 No



#### Section 5.

#### **Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Wise reports personal fees from Contrafect, during the conduct of the study; grants and personal fees from AstraZeneca / Medimmune / Pearl, grants and personal fees from Boehringer Ingelheim, personal fees from Contrafect, personal fees from Pulmonx, personal fees from Roche, personal fees from Spiration, personal fees from Sunovion, grants from Pearl Therapeutics, personal fees from Merck, personal fees from Circassia, personal fees from Pneuma, personal fees from Verona, personal fees from Mylan/Theravance, personal fees from Propeller Health, grants from Sanofi-Aventis, personal fees from AbbVie, grants and personal fees from GSK, personal fees from Novartis, personal fees from Kiniksa, outside the submitted work.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Gordon Ralph	2. Surname (Last Name) Corey		3. Date 11-November-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's N Vance Fowler, MD, MH	
5. Manuscript Title Efficacy and Safety of Exebacase Addec Bloodstream Infections Including Endo		ersus Antibiotic Therapy Alo	one for Staphylococcus aureus
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under C	onsideration for Publ	ication	
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?			-
Are there any relevant conflicts of inter	est? 🖌 Yes 🗌 No		
If yes, please fill out the appropriate info Excess rows can be removed by pressin	•	ave more than one entity p	ress the "ADD" button to add a row.
Name of Institution/Company	Grant•	on-Financial Support? Other? Co	omments
Contrafect		con	sultant

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  $\checkmark$  Yes  $\square$  No

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Arsanis		✓			Scientific Advisory Board, consultant
Medtronic		$\checkmark$			Scientific Advisory Board/study design group
Melinta		$\checkmark$			Scientific Advisory Board, consultant



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Motif		$\checkmark$			consultant	
Paratek		$\checkmark$			Scientific Advisory Board, consultant	
Regeneron		$\checkmark$			consultant	
SCPharma		$\checkmark$			consultant	
Shionogi		$\checkmark$			consultant, adjudication committee	
Tetraphase		$\checkmark$			Scientific Advisory Board	
The Medicines Company		$\checkmark$			consultant	

## Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 🗸 No

## Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Corey reports personal fees from Contrafect, during the conduct of the study; personal fees from Arsanis, personal fees from Medtronic, personal fees from Melinta, personal fees from Motif, personal fees from Paratek, personal fees from Regeneron, personal fees from SCPharma, personal fees from Shionogi, personal fees from Tetraphase, personal fees from The Medicines Company, outside the submitted work.



**Evaluation and Feedback** 



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Marcus	2. Surname (Last Name) Zervos		3. Date 13-November-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Vance Fowler	Name
5. Manuscript Title Efficacy and Safety of Exebacase Addec Bloodstream Infections Including Endo		rsus Antibiotic Therapy Al	one for Staphylococcus aureus
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under C	onsideration for Publ	ication	
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?	g but not limited to grants, c		
Are there any relevant conflicts of intere If yes, please fill out the appropriate info	ormation below. If you ha	ave more than one entity p	press the "ADD" button to add a row.
Excess rows can be removed by pressin			
Name of Institution/Company	Grant	on-Financial Support? Other? C	omments
ContraFect Corporation		Co	nsulting fees

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  $\checkmark$  Yes  $\square$  No

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Pfizer	$\checkmark$					
Merck	$\checkmark$					
Medimmune	$\checkmark$					



Name of Entity	Grant? Personal N Fees?	on-Financial Support?	? Comments			
Genetech						
Section 4. Intellectual Propert	y Patents & Copy	rights				
Do you have any patents, whether plann	ed, pending or issued,	broadly relevant to t	ne work? 🗌 Yes 🖌 No	)		
Section 5. Relationships not o	overed above					
Are there other relationships or activities potentially influencing, what you wrote	•		ced, or that give the appear	ance of		
Yes, the following relationships/conc	litions/circumstances a	re present (explain b	elow):			
✓ No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to				ure statements.		
Section 6. Disclosure Stateme	nt	_				
Based on the above disclosures, this form below.	n will automatically gei	nerate a disclosure sta	atement, which will appear i	in the box		

Dr. Zervos reports personal fees from ContraFect Corporation, during the conduct of the study; grants from Pfizer, grants from Merck, grants from Medimmune, grants from Genetech, outside the submitted work.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Povalties: Funds are coming in to you or your institution due to you



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Pamela	2. Surname (Last Name) Douglas		3. Date 13-November-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Na Vance Fowler	ame
5. Manuscript Title Efficacy and Safety of Exebacase Addec Bloodstream Infections Including Endo		sus Antibiotic Therapy Alo	ne for Staphylococcus aureus
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under C	onsideration for Publi	cation	
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da		
Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressin	ormation below. If you hav	ve more than one entity pro	ess the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	n-Financial Support? Other? Co	omments
ContraFect			
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. U	se one line for each entity;	add as many lines as you need by
Are there any relevant conflicts of intere	est? Yes 🖌 No		
Section 4. Intellectual Proper	rty Patents & Copyri	ghts	
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work	Yes 🖌 No</td



#### Section 5.

#### **Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Douglas reports grants from ContraFect, during the conduct of the study.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Cara	2. Surname (Last Name) Cassino		3. Date 14-November-2019
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's N Vance Fowler	Name
5. Manuscript Title Efficacy and Safety of Exebacase Addec Bloodstream Infections Including Endo		ersus Antibiotic Therapy Ale	one for Staphylococcus aureus
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under C	onsideration for Publ	ication	
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?			-
Are there any relevant conflicts of intere			
If yes, please fill out the appropriate info Excess rows can be removed by pressin		ave more than one entity p	ress the "ADD" button to add a row.
Name of Institution/Company	Grant•	on-Financial Support? Other? C	omments
ContraFect Corporation		Full	I time Employee of ContraFect

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

No

Are there any relevant conflicts of interest?  $\checkmark$  Yes

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
ContraFect Corporation				$\checkmark$	Full time employee of ContraFect



# Section 4. Intellectual Property -- Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Cassino reports other from ContraFect Corporation , during the conduct of the study; other from ContraFect Corporation, outside the submitted work.

## **Evaluation and Feedback**